FY2025 EPS Estimates for Rezolute Cut by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings estimates for Rezolute, lowering the forecast to ($1.02) per share from a previous estimate of ($0.97).
• Rezolute reported a quarterly EPS of ($0.27), which fell short of the analysts' consensus estimate of ($0.22) by $0.05.
• Analysts maintain a generally positive outlook, with one firm rating the stock as a "sell" while others have issued "buy" or "outperform" ratings, and an average target price of $11.83.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Rezolute in a research note issued to investors on Thursday, July 24th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings of ($1.02) per share for the year, down from their prior estimate of ($0.97). The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05).

Several other research firms have also recently issued reports on RZLT. Wedbush reissued an "outperform" rating and issued a $12.00 price objective on shares of Rezolute in a research report on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and issued a $14.00 price objective on shares of Rezolute in a research report on Monday, April 28th. Finally, Wall Street Zen cut shares of Rezolute from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $11.83.

Rezolute Price Performance

Rezolute stock opened at $6.30 on Monday. The stock has a market cap of $548.10 million, a price-to-earnings ratio of -5.48 and a beta of 1.03. Rezolute has a 1 year low of $2.21 and a 1 year high of $6.38. The firm has a 50-day moving average of $4.59 and a two-hundred day moving average of $4.13.

Institutional Investors Weigh In On Rezolute

Large investors have recently modified their holdings of the business. Alpine Global Management LLC bought a new stake in shares of Rezolute in the 4th quarter valued at about $54,000. Jeppson Wealth Management LLC bought a new stake in shares of Rezolute in the 1st quarter valued at about $35,000. Retireful LLC bought a new stake in shares of Rezolute in the 2nd quarter valued at about $70,000. Paloma Partners Management Co bought a new stake in shares of Rezolute in the 1st quarter valued at about $48,000. Finally, Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Rezolute by 48.5% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company's stock valued at $97,000 after purchasing an additional 6,470 shares in the last quarter. Institutional investors own 82.97% of the company's stock.

Insider Activity at Rezolute

In other Rezolute news, Director Young-Jin Kim purchased 1,230,769 shares of Rezolute stock in a transaction dated Friday, June 13th. The stock was acquired at an average price of $3.25 per share, for a total transaction of $3,999,999.25. Following the acquisition, the director owned 8,423,386 shares in the company, valued at $27,376,004.50. This trade represents a 17.11% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have bought 1,241,345 shares of company stock valued at $4,041,196. Insiders own 18.39% of the company's stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.